Sneezing News and Research

RSS

When it comes to catching an infection, planes no riskier than airports

A study carried out by the Australian Transport Safety Bureau has found there is no greater risk of catching an infection on a plane than in any other crowded and confined space.

10 Jun 2008

New hay fever jab promises year long relief for sufferers

Relief is in sight for millions of hay fever sufferers with the promise of a jab, which lasts for a year, that significantly reduces symptoms.

15 May 2008

Study explains why steroid therapy for sinusitis and asthma loses its punch over time

Scientists at Johns Hopkins have outlined a new path for potential therapies to combat inflammation associated with sinusitis and asthma based on a new understanding of the body's earliest immune response in the nose and sinus cavities.

29 Apr 2008

Taro Pharmaceutical receives final FDA approval for Cetirizine Hydrochloride oral solution

Taro Pharmaceutical Industries Ltd. reported today that it has received final approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for cetirizine hydrochloride oral solution, 1 mg / 1 mL ("Cetirizine Oral Solution").

22 Apr 2008

CDC issues measles travel warning for Israel

As Americans travel to Israel for the Jewish holiday of Passover, the Centers for Disease Control and Prevention advises all travelers to ensure they are protected from measles before departing, because of a measles outbreak in Israel.

16 Apr 2008

Alcon's PATANASE nasal spray approved by FDA for treatment of nasal allergy symptoms

Alcon, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved PATANASE(R) (olopatadine hydrochloride) nasal spray for the relief of the symptoms of seasonal allergic rhinitis in patients 12 years of age and older.

16 Apr 2008

Allergies dramatically impact sufferers' moods and how they feel about themselves

A new Harris Interactive phone survey conducted among 1,000 allergy sufferers, 1,000 consumers (both allergy sufferers and non-sufferers) and 300 physicians shows that beyond the sneezing, sniffling and watery eyes, allergies also have deep and emotional impacts on a sufferer's mood and self-perceptions.

24 Mar 2008

Physical therapy helps symptoms of urinary incontinence in women

A study published in the Annals of Internal Medicine (March 18, 2008) reports that pelvic floor muscle training, in conjunction with bladder training, resolved the symptoms of urinary incontinence in women.

20 Mar 2008

New research shows why winter is the season for flu

Researchers in the United States believe they have discovered why flu and other respiratory viruses are more prevalent in winter.

3 Mar 2008

FDA approves XYZAL (levocetirizine dihydrochloride) for allergies and chronic idiopathic urticaria

UCB and sanofi-aventis have announced that the U.S. Food and Drug Administration (FDA) approved a New Drug Application (NDA) for XYZAL (levocetirizine dihydrochloride) 0.5 mg/mL oral solution, a prescription antihistamine indicated for the relief of symptoms associated with indoor and outdoor allergies, as well as the treatment of chronic idiopathic urticaria.

20 Feb 2008

Probiotics help keep elite athletes fit and well

According to the latest Australian research the immune system of long-distance runners was enhanced by probiotics - dietary supplements containing potentially beneficial bacteria or yeasts.

13 Feb 2008

New sugary insights into H5N1 avian flu virus

Scientists have identified a key factor that determines the ability of influenza viruses to infect cells of the human upper respiratory tract - a necessary step for sustaining spread between people.

7 Jan 2008

FDA approves formulations of Zyrtec (cetirizine HCl) for nonprescription use

The U.S. Food and Drug Administration has approved tablet, chewable tablet, and syrup formulations of Zyrtec (cetirizine HCl) for nonprescription use.

21 Nov 2007

La Jolla Institute for Allergy & Immunology to perform study on allergy molecular causes

A major study that will provide a new window into understanding and potentially treating allergies will be conducted by the La Jolla Institute for Allergy & Immunology (LIAI) under a $5 million federal contract.

14 Nov 2007

FDA approves new nonprescription allergy drug Zyrtec-D

The Food and Drug Administration (FDA) has approved Zyrtec-D (cetirizine HCl 5 mg and pseudoephedrine HCl 120 mg), an allergy drug, for nonprescription use in adults and children 12 years of age and older. This drug combines an antihistamine with a nasal decongestant.

13 Nov 2007